Nacuity Pharmaceuticals Announces Positive Data from Clinical Trial Evaluating NPI-001 to Treat Retinitis Pigmentosa Associated with Usher Syndrome
September 11, 2025 09:00 ET Â | Source: Nacuity Pharmaceuticals, Inc. NPI-001 shows…
Servier acquires potential treatment for Fragile X syndrome, the most common genetic cause of autism spectrum disorder
Servier acquires KER-0193, a potential treatment for Fragile X syndrome, developed by…
UCB presents latest research and clinical advancement across leading epilepsy portfolio at International Epilepsy Congress
26 scientific abstracts, including two oral presentations, demonstrate UCB's ongoing commitment to advancing…
Galapagos NV Announces U.S. FDA Regenerative Medicine Advanced Therapy (RMAT) Designation Granted to GLPG5101 for the Treatment of Relapsed/Refractory Mantle Cell Lymphoma
Mechelen, Belgium; August 6, 2025, 7:30 CET; regulated information – inside information…
Ultragenyx Receives Complete Response Letter from FDA for UX111 AAV Gene Therapy to Treat Sanfilippo Syndrome Type A (MPS IIIA)
July 11, 2025 16:30 ET Â | Source: Ultragenyx Pharmaceutical Inc. Complete Response…